Meulenbeld, H.J.

patient cancer docetaxel prostate prostate cancer study treatment survival response group trial phase chemotherapy danusertib progression chapter aurora tumor month kinase disease metastatic mitoxantrone therapy prednisone oncol lenalidomide effect combination bone metastases ridaforolimu result inhibitor grade activity toxicity randomized risedronate psa response metastatic prostate cancer bicalutamide metastase model agent analysis bisphosphonate zibotentan efficacy metastatic crpc estramustine wit r xenograft benefit docetaxel-based chemotherapy baseline zoledronic acid receptor androgen growth docetaxel-based event disease progression safety aurora kinases level placebo cycle pathway table target pi 3k pathway inhibition orthotopic psa progression castration-resistant carcinoma castration criteria development survival benefit